B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome

NCT01156922 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
8
Enrollment
OTHER
Sponsor class

Stopped Difficulties in logistics handling the very severe patients (travel, hospital stay, follow-up)

Conditions

Interventions

Sponsor

Haukeland University Hospital